Scarica l'app Stockscreener
17.30
2.86%
-0.51
Dopo l'orario di chiusura:
17.68
0.38
+2.20%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché APLS Giù?
Forum
Previsione
Precedente Chiudi:
$17.81
Aprire:
$17.52
Volume 24 ore:
2.96M
Relative Volume:
1.34
Capitalizzazione di mercato:
$2.56B
Reddito:
$715.22M
Utile/perdita netta:
$-250.10M
Rapporto P/E:
-8.5222
EPS:
-2.03
Flusso di cassa netto:
$-205.58M
1 W Prestazione:
-14.95%
1M Prestazione:
-11.78%
6M Prestazione:
-42.29%
1 anno Prestazione:
-59.31%
Intervallo 1D:
$17.23
$18.10
Intervallo di 1 settimana:
$16.65
$20.59
Portata 52W:
$16.65
$43.99
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Nome
Apellis Pharmaceuticals Inc
Settore
Industria
Telefono
617-977-5700
Indirizzo
100 FIFTH AVENUE, WALTHAM, KY
Confronta APLS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
17.30 | 2.56B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-09 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-05-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Downgrade | Goldman | Buy → Neutral |
| 2024-11-21 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-16 | Iniziato | William Blair | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Neutral |
| 2024-02-05 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-02 | Iniziato | Mizuho | Neutral |
| 2023-10-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Reiterato | Citigroup | Buy |
| 2023-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-19 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-17 | Ripresa | Stifel | Buy |
| 2022-04-14 | Downgrade | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-29 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Reiterato | BMO Capital Markets | Outperform |
| 2021-09-10 | Reiterato | Credit Suisse | Neutral |
| 2021-09-10 | Reiterato | Needham | Buy |
| 2021-09-10 | Reiterato | Oppenheimer | Outperform |
| 2021-09-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-08-19 | Iniziato | Jefferies | Buy |
| 2021-08-19 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2020-11-19 | Iniziato | Needham | Buy |
| 2020-09-01 | Iniziato | Stifel | Buy |
| 2020-07-20 | Iniziato | ROTH Capital | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Neutral |
| 2020-04-01 | Iniziato | Raymond James | Strong Buy |
| 2020-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-11 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2020-01-07 | Iniziato | SVB Leerink | Mkt Perform |
| 2019-12-19 | Iniziato | BofA/Merrill | Buy |
| 2019-11-22 | Iniziato | Wedbush | Underperform |
| 2019-11-05 | Iniziato | Credit Suisse | Neutral |
| 2019-08-01 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie
APLS: Apellis Pharmaceuticals Stock Downgraded by B of A Securit - GuruFocus
Raymond James Downgrades Apellis Pharmaceuticals (BIT:1APLS) - Nasdaq
Raymond James Downgrades Apellis Pharmaceuticals (APLS) with Pri - GuruFocus
Sector Update: Health Care - marketscreener.com
Apellis Pharmaceuticals Stumbles Over Funding And Sales Hurdles - Finimize
Raymond James Downgrades Apellis Pharmaceuticals (APLS) with Price Target Cut | APLS Stock News - GuruFocus
Apellis Pharmaceuticals downgraded by Raymond James due to ’added uncertainty’ - Investing.com Canada
Is Apellis Pharmaceuticals, Inc. (APLS) The Best Stock That Will Bounce Back? - Insider Monkey
Apellis (APLS) Faces Downgrade Amid Sales Volatility Concerns | - GuruFocus
Analysts Just Slashed Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) EPS Numbers - simplywall.st
BofA Adjusts Apellis (APLS) Rating to Neutral, Lowers Price Target | APLS Stock News - GuruFocus
Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say - MSN
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates - MSN
11 Stocks That Will Bounce Back According to Analysts - Insider Monkey
Apellis Pharmaceuticals (APLS) Analyst Rating Update by RBC Capi - GuruFocus
Apellis Pharmaceuticals (APLS) Analyst Rating Update by RBC Capital | APLS Stock News - GuruFocus
Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down - Zacks Investment Research
Apellis (APLS) Price Target Reduced by Scotiabank Analyst | APLS Stock News - GuruFocus
Apellis Pharmaceuticals (APLS) Price Target Lowered by Scotiabank | APLS Stock News - GuruFocus
Apellis Pharmaceuticals (APLS): Wells Fargo Lowers Price Target to $26 | APLS Stock News - GuruFocus
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2025 Earnings Call Transcript - Insider Monkey
Apellis Pharmaceuticals (APLS) Target Price Lowered by Analyst | APLS Stock News - GuruFocus
Optimistic Growth Potential for Apellis Pharmaceuticals Despite Temporary Setbacks - TipRanks
Apellis Pharmaceuticals (APLS) Price Target Reduced by Analyst | APLS Stock News - GuruFocus
Apellis Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Apellis Pharmaceuticals Inc (APLS) Q1 2025 Earnings Call Highlights: Strong Market Leadership ... - Yahoo Finance
Fierce Biotech Layoff Tracker 2025: Insitro shrinks team by 22%; Shape ships out staff - Fierce Biotech
Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results - Barchart.com
Decoding Apellis Pharmaceuticals Inc (APLS): A Strategic SWOT In - GuruFocus
Apellis Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Why Apellis Pharmaceuticals (APLS) Stock is Declining - GuruFocus
Why Apellis Pharmaceuticals Wilted on Wednesday - MSN
Why Apellis Pharmaceuticals Wilted on Wednesday - The Motley Fool
APLS: Apellis Pharmaceuticals Maintains Buy Rating Amid Price Target Cut | APLS Stock News - GuruFocus
Transcript : Apellis Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 07, 2025 - marketscreener.com
Earnings call transcript: Apellis Pharmaceuticals misses Q1 2025 estimates By Investing.com - Investing.com Nigeria
Earnings call transcript: Apellis Pharmaceuticals misses Q1 2025 estimates - Investing.com
Apellis Pharmaceuticals stock tumbles on Q1 revenue miss, inventory issues By Investing.com - Investing.com India
Apellis Pharmaceuticals stock tumbles on Q1 revenue miss, inventory issues - Investing.com
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results - The Manila Times
Apellis (APLS) Sees Q1 Revenue Miss as Strategic Growth Continues | APLS Stock News - GuruFocus
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
BRIEF-Apellis Pharmaceuticals Q1 Basic EPS USD -0.74 - TradingView
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - TradingView
Apellis Pharmaceuticals Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - Louisiana First News
Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Globe and Mail
Press Release Distribution & PR Platform - ACCESS Newswire
Apellis Pharmaceuticals to Present Q1 2025 Results: Complement Medicine Leader's Financial Update - Stock Titan
Apellis (APLS) Receives Overweight Rating and Positive Outlook f - GuruFocus
Apellis Pharmaceuticals Inc Azioni (APLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.84%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):